Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$1.02
+4.2%		$0.98
$0.71
▼
$3.07
$26.13M0.51114,418 shs55,896 shs
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$1.15
-4.2%		$1.39
$1.15
▼
$7.81
$6.67M-2.0594,363 shs80,827 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.30
-5.1%		$1.89
$0.13
▼
$1.04
$25.04M1.581.05 million shs110,445 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$6.51
$4.01
$1.11
▼
$17.50
$27.46M0.382,778 shs1,912 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
+4.19%+2.00%+2.00%-15.70%-65.77%
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-4.17%-11.54%-17.27%-27.67%-84.85%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-5.11%-14.47%-32.99%-9.72%-78.96%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+58.87%+58.87%+35.70%-50.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$1.02
+4.2%		$0.98
$0.71
▼
$3.07
$26.13M0.51114,418 shs55,896 shs
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$1.15
-4.2%		$1.39
$1.15
▼
$7.81
$6.67M-2.0594,363 shs80,827 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$1.30
-5.1%		$1.89
$0.13
▼
$1.04
$25.04M1.581.05 million shs110,445 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$6.51
$4.01
$1.11
▼
$17.50
$27.46M0.382,778 shs1,912 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
+4.19%+2.00%+2.00%-15.70%-65.77%
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-4.17%-11.54%-17.27%-27.67%-84.85%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-5.11%-14.47%-32.99%-9.72%-78.96%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+58.87%+58.87%+35.70%-50.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
1.00
SellN/AN/A
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.00
HoldN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.00
N/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ACXP, ZIVO, VIRI, and ABVC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/11/2026
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
7/17/2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/AN/AN/AN/A$0.52 per shareN/A
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$2.07 per shareN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,732.17N/AN/A($0.81) per share-8.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$7.91M-$0.30N/AN/AN/AN/A-47.68%-30.97%11/16/2026 (Estimated)
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$7.97M-$2.69N/AN/AN/AN/A-124.73%-87.48%11/11/2026 (Estimated)
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.40N/AN/AN/AN/AN/A-2,240.92%12/2/2026 (Estimated)

Latest ACXP, ZIVO, VIRI, and ABVC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026Q3 2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.45N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.3767-$0.53-$0.1533-$0.53N/AN/A
8/12/2026Q2 2026
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$0.40-$0.03+$0.37-$0.03$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/AN/AN/AN/AN/A
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A
0.07
0.07
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
3.88
3.88
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
11.38%
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
19.00%
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
6.50%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
21.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
1926.69 million21.62 millionNot Optionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
45.56 million5.20 millionNo Data
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionNo Data
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs
Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72
November 1, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/zivo-bioscience-zivo-price-target-increased-by-50000-to-3672/ar-AA1jflXo
Zivo Bioscience Inc ZIVO
November 1, 2023  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC BioPharma stock logo

ABVC BioPharma NASDAQ:ABVC

$1.02 +0.04 (+4.19%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$0.98 -0.04 (-4.31%)
As of 05:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$1.15 -0.05 (-4.17%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$1.20 +0.05 (+4.35%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$1.30 -0.07 (-5.11%)
As of 10/13/2026

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$6.51 0.00 (0.00%)
As of 10/13/2026 03:53 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas